Atea Pharmaceuticals, Inc.
AVIR
$3.06
-$0.04-1.29%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 21.91M | 19.92M | 23.21M | 57.58M | 17.34M |
| Gross Profit | -21.91M | -19.92M | -23.21M | -57.58M | -17.34M |
| SG&A Expenses | 13.36M | 11.04M | 12.22M | 12.23M | 11.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.27M | 30.97M | 35.43M | 69.81M | 28.87M |
| Operating Income | -35.27M | -30.97M | -35.43M | -69.81M | -28.87M |
| Income Before Tax | -33.32M | -30.93M | -40.28M | -62.94M | -38.82M |
| Income Tax Expenses | 225.00K | 226.00K | 243.00K | 231.00K | 349.00K |
| Earnings from Continuing Operations | -33.54M | -31.15M | -40.52M | -63.17M | -39.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.54M | -31.15M | -40.52M | -63.17M | -39.16M |
| EBIT | -35.27M | -30.97M | -35.43M | -69.81M | -28.87M |
| EBITDA | -35.16M | -30.86M | -35.33M | -69.70M | -28.77M |
| EPS Basic | -0.40 | -0.37 | -0.48 | -0.75 | -0.47 |
| Normalized Basic EPS | -0.22 | -0.18 | -0.21 | -0.47 | -0.16 |
| EPS Diluted | -0.40 | -0.37 | -0.48 | -0.75 | -0.47 |
| Normalized Diluted EPS | -0.22 | -0.18 | -0.21 | -0.47 | -0.16 |
| Average Basic Shares Outstanding | 84.46M | 84.42M | 84.25M | 83.92M | 83.44M |
| Average Diluted Shares Outstanding | 84.46M | 84.42M | 84.25M | 83.92M | 83.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
